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Aims Cardiac dyssynchrony is common in patients with heart failure, whether or not they have ischaemic heart disease
(IHD). The effect of the underlying cause of cardiac dysfunction on the response to cardiac resynchronization
therapy (CRT) is unknown. This issue was addressed using data from the CARE-HF trial.
Methods
and results
Patients (n ¼ 813) were grouped by heart failure aetiology (IHD n ¼ 339 vs. non-IHD n ¼ 473), and the primary
composite (all-cause mortality or unplanned hospitalization for a major cardiovascular event) and principal secondary
(all-cause mortality) endpoints analysed. Heart failure severity and the degree of dyssynchrony were compared
between the groups by analysing baseline clinical and echocardiographic variables. Patients with IHD were more
likely to be in NYHA class IV (7.5 vs. 4.0%; P ¼ 0.03) and to have higher NT-proBNP levels (2182 vs. 1725 pg/L),
indicating more advanced heart failure. The degree of dyssynchrony was more pronounced in patients without
IHD (assessed using mean QRS duration, interventricular mechanical delay, and aorta-pulmonary pre-ejection
time). Left ventricular ejection fraction and left ventricular end-systolic volume improved to a lesser extent in the
IHD group (4.53 vs. 8.50% and 235.68 vs. –58.52 cm
3). Despite these differences, CRT improved all-cause mortality,
NYHA class, and hospitalization rates to a similar extent in patients with or without IHD.
Conclusion The beneﬁts of CRT in patients with or without IHD were similar in relative terms in the CARE-HF study but as
patients with IHD had a worse prognosis, the beneﬁt in absolute terms may be greater.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
The overall goal with the treatment of heart failure patients is to
improve quality of life and symptoms such as tiredness and dys-
pnoea,reducemorbidityleadingtohospitalization,andimprovesur-
vival. Despite the remarkable advances in pharmacological
treatment of this condition, many patients remain symptomatic
with a poor prognosis.
1,2 QRS prolongation, thought to denote
intraventricular conduction abnormalities, is present in 25% of
patientswithheartfailureandhasbeenassociatedwithapoorprog-
nosis.
3,4 The development of a pacemaker with an extra third lead
placed epicardially on the left ventricle via the coronary sinus has
provided an effective treatment for dyssynchrony. Cardiac resyn-
chronization therapy (CRT) has been shown in several trials to
reduce dyssynchrony and improve symptoms, quality of life, and
exercise capacity in patients with heart failure.
5 The COMPANION
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and hospitalizations,
6 although a statistically signiﬁcant reduction in
mortality could only be demonstrated when CRT was combined
with a deﬁbrillator. The CARE-HF study demonstrated that CRT
alone could reduce the risk of death and unplanned hospitalization
substantially compared with optimal pharmacological treatment
for heart failure (hazard ratio 0.64, 95% conﬁdence interval 0.48–
0.85, P , 0.002).
7 However, the response to CRT is variable, and
selecting patients who will respond to this treatment is of concern
to patients, doctors, and those who provide health-care funding.
8
Clinically and mechanically, patients with ischaemic heart disease
(IHD) differ from patients with dilated cardiomyopathy.
9,10
ResponsetoCRTtreatmentmaydependontheunderlyingmyocar-
dial pathology, especially regional variations in function and the
extent of scar. The aim of the present study was to examine
whether patients with and without IHD differed with regard to
the response to CRT by analysing primary and secondary endpoints
in the CARE-HF trial.
Methods
The design and results of the CARE-HF study have been reported else-
where.
11 Brieﬂy, heart failure patients were included if they fulﬁlled the
following criteria: .18 years of age; recent NYHA class III or IV symp-
toms despite optimal pharmacological therapy; left ventricular (LV)
ejection fraction (EF)  35%; LV end-diastolic diameter (LVEDD)
 30 mm/m
2; and QRS width  120 ms. If QRS width was 120–
149 ms, two out of three criteria of dyssynchrony were also required:
an aortic pre-ejection delay .140 ms; an interventricular mechanical
delay (IVMD) .40 ms; or, delayed activation of the posterolateral
LV wall. A total of 813 patients were randomly assigned to either
medical therapy alone or medical therapy in combination with CRT
and followed for mean 29.4 months (range 18–44.7 months). In this
analysis, patients were grouped according to heart failure aetiology:
IHD n ¼ 339 (41.8%) and non-IHD n ¼ 474 (58.2%) for the analysis
of primary composite endpoint (all-cause mortality or unplanned hos-
pitalization for a major cardiovascular event) and secondary endpoint
(death from any cause). Baseline characteristics of the two patient
groups were compared and an evaluation of differences in outcome
conducted using: the Minnesota living with heart failure questionnaire
(MLWHF); NYHA class; QRS duration—at 18 months; echocardio-
graphic variables [mitral regurgitation, LVEDD, LV end-systolic dia-
meter (LVESD), LVEF, and IVMD] at 3 and 18 months of assigned
therapy. Patients were deﬁned as having IHD if they had a history of
myocardial infarction, and/or a coronary angiogram indicating major
disease and/or a history of coronary artery by-pass graft and/or angio-
plasty. Previous reports have deﬁned aetiology by the principal diagno-
sis but any diagnosis of IHD was used in this analysis, which accounts
for minor discrepancies in numbers of patients between reports.
7
Statistical methods
All statistical tests were two sided, and an a value of 5% was con-
sidered to be nominally statistically signiﬁcant. No adjustment was
made for multiple testing. Median values were compared using the
Kruskal–Wallis test, difference in means was assessed using general-
ized mixed models with an identity link and normal error, incorporat-
ing baseline values as patient level covariates and the investigational
sites as random effects. Interaction terms to describe the relationship
between a patient level characteristic of interest and the effects of
treatment were estimated in the multivariable models through ﬁtting
terms describing the main effects of the characteristic of interest and
a treatment, and an interaction term. Survival functions were con-
trasted using approximate frailty models, which included investigational
sites as grouped frailties. These models were also used to estimate
interaction effects for the primary and secondary outcomes. All ana-
lyses were conducted in SAS 9.1 (SAS Institute, Cary, NC, USA).
The authors had full access to the data and take responsibility of its
integrity. All authors have read and agreed to the manuscript as written.
Results
Of 339 patients with IHD, 186 (54.9%) were assigned to CRT and
153 (45.1%) to the control group, and of patients with dilated car-
diomyopathy or other causes of heart failure (non-IHD), 223
(47.2%) were assigned to CRT and 250 (52.9%) to the control
group. Baseline characteristics of the patients are presented in
Table 1. The clinical characteristics in the two patient groups dif-
fered in many aspects. Patients with IHD were older (P , 0.001)
and were more often men (P , 0.001). High-dose furosemide
(56 vs. 34%, respectively; P , 0.001) was more frequently used
in those with IHD, whereas beta-blockers (67 vs. 76%, respectively;
P ¼ 0.003) and angiotensin-converting enzyme-inhibitors (92.9 vs.
96.2%, respectively; P ¼ 0.06) were used more frequently in
patients without IHD (Table 1). More patients with IHD were in
NYHA class IV, a difference that was statistically signiﬁcant in
both the CRT and medical therapy group (Table 1). Furthermore,
median NT-proBNP levels were higher at baseline in patients with
IHD, both for CRT and medically treated patients (Table 1).
The proportion of patients with echocardiographic signs of dys-
synchrony at baseline, including IVMD .40 ms, aorta pre-ejection
time .140 ms, and a QRS duration  150 ms at baseline, was
greater in patients without IHD.
The effect of CRT on echocardiographic variables by aetiology
and assigned treatment at 3 months are shown in Table 2. At this
time, reductions in IVMD, mitral regurgitation, and LV end-systolic
volume and improvement in LVEF with CRT were already substan-
tial and no clear difference in the magnitude of effect of CRT
between patients with and without IHD had appeared.
Clinical outcome variables measured during the study at 18
months’ follow-up are presented in Table 3. Mean QRS duration
at 18 months was shortened and quality of life and NYHA class
were improved by CRT in both patient groups. There was a
trend for a greater effect of CRT on the primary outcome
measure of all-cause mortality and cardiovascular hospitalization,
in patients without IHD (hazard ratio 0.48; 95% CI 0.35–0.65)
when compared with those with IHD (hazard ratio 0.72; 95% CI
0.54–0.95) (Table 4, Figures 1 and 2). However, the interaction
term comparing these two hazard functions was not statistically
signiﬁcant, indicating that the apparent difference could plausibly
be explained by chance (P ¼ 0.06). The effect of CRT on all-cause
mortality was very similar [hazard ratio 0.60 (95% CI 0.42–0.86)
and 0.59 (95% CI 0.37–0.92) for IHD and no IHD, respectively].
Discussion
Previous reports and theoretical considerations have led many to
believe that the beneﬁts of CRT are less in patients with IHD
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Table 1 Baseline characteristics in the 813 patients enrolled in CARE-HF
CRT group Medical therapy group IHD vs. non-IHD
(P-value)
IHD n 5 186 Non-IHD n 5 223 IHD n 5 153 Non-IHD n 5 250
Male sex, n (%) 154 (82.80) 150 (67.26) 132 (86.27) 161 (64.40) ,0.0001
Age (years), mean (SD) 67.69 (9.02) 63.73 (10.72) 67.94 (8.82) 63.44 (10.41) ,0.0001
NYHA class IV, n (%) 14 (7.53) 9 (4.04) 14 (9.15) 13 (5.20) 0.039
Systolic blood pressure (mmHg), mean (SD) 116.69 (16.44) 118.21 (17.41) 115.45 (18.17) 118.70 (17.89) 0.12
LVEF (%), mean (SD) 25.30 (5.72) 25.47 (6.19) 26.20 (6.01) 25.27 (6.15) 0.19
LVESV (cm
3), mean (SD) 120.86 (42.66) 129.98 (52.83) 123.70 (40.09) 130.81 (54.79) 0.22
Mitral regurgitation, median (IQR)
a 23.57 (14.37) 23.59 (16.15) 23.11 (13.18) 24.51 (15.33) 0.95
ACE-I/ARB, n (%) 175 (94.09) 212 (95.07) 140 (91.50) 243 (97.20) 0.052
Digoxin, n (%) 75 (40.32) 90 (40.36) 54 (35.29) 127 (50.80) 0.031
b-Blocker, n (%) 124 (66.67) 174 (78) 102 (66.67) 186 (74.40) 0.003
Loop diuretics  80 mg per day furosemide or equivalent, n (%) 101 (54.30) 74 (33.18) 89 (58.17) 88 (35.20) ,0.0001
GFR (mL/min), median (IQR) 56.93 (43.74–70.63) 61.43 (49.41–75.61) 52.51 (42.75–65.84) 64.16 (49.99–77.54) ,0.0001
NT-proBNP (pg/mL), median (IQR) 2182 (888–4888) 1725 (651–3992) 2064 (1057–4787) 1658 (592–3611) 0.0021
QRS (ms), mean (SD) 163.47 (18.95) 167.41 (20.85) 161.84 (20.33) 166.25 (17.57) 0.0012
IVMD .40, n (%) 64 (38.10) 117 (59.39) 43 (31.85) 144 (61.28) ,0.0001
IVMD (ms), mean (SD) 41.44 (26.30) 56.70 (29.61) 37.86 (24.55) 54.64 (26.75) ,0.0001
Aorta pre-ejection time  140 ms, n (%) 101 (58.72) 166 (82.59) 77 (55.40) 193 (80.75) ,0.0001
Pulmonary pre-ejection time  140 ms, n (%) 25 (14.88) 45 (22.61) 23 (17.04) 51 (21.43) 0.0471
ACE-I, angiotensin-converting enzyme-inhibitor; ARB, angiotensin receptor blocker; GFR, glomerular ﬁltration rate; IVMD, interventricular mechanical delay; NT-proBNP, brain natriuretic peptide.
aThe area of the mitral regurgitation jet was calculated as the area of the colour ﬂow Doppler regurgitant jet divided by the area of the left atrium in systole, both in square centimetres.
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4compared with those without IHD. This analysis of CARE-HF
suggests that the long-term effects of CRT on symptoms, quality
of life, morbidity, and mortality are similar in patients with and
without IHD. These beneﬁts were observed even though patients
with IHD had less evidence of dyssynchrony, lower arterial
pressure, worse renal function, higher doses of diuretic therapy,
more severe cardiac dysfunction, more severe heart failure, and
a worse overall prognosis. Accordingly, patients with IHD should
not be denied CRT on the grounds of the aetiology of their LV dys-
function alone. Of note, the severity and complexity of heart
failure in patients with IHD was associated with lower uptake of
guideline-indicated therapy at baseline, such as beta-blockers.
The initial improvement in cardiac function, both in terms of
reduced mitral regurgitation and improved LVEF, was similar in
patients with and without IHD, although trends favoured patients
without IHD. Patients with IHD had less dyssynchrony and this
................................................... ....................................................
...............................................................................................................................................................................
Table 2 Echocardiographic and quality of life outcome differences at 3 months’ follow-up
CRT group Medical therapy group P-value for
interaction
a
IHD Non-IHD Non-IHD IHD
Mitral regurgitation index,
median (IQR)
16.75 (9.73–26.13) 13.37 (5.48–24.63) 19.03 (11.51–31.90) 18.05 (9.51–28.77) 0.1866
LVEDD (cm), mean (SD) 7.15 (0.99) 6.90 (1.25) 7.20 (1.11) 7.26 (1.05) 0.2858
LVESV (cm
3), mean (SD) 193.99 (69.36) 194.01 (104.74) 233.18 (98.36) 231.54 (86.05) 0.0354
LVEF (%), mean (SD) 29.08 (6.90) 30.59 (8.19) 26.56 (6.92) 26.31 (6.50) 0.3550
IVMD (ms), mean (SD) 22.38 (20.03) 32.54 (22.52) 52.86 (29.24) 39.30 (27.07) 0.3570
MLWHF, mean (SD) 31.29 (19.74) 41.50 (20.49) 35.56 (21.68) 30.25 (22.00) 0.1542
IHD, ischaemic heart disease; IVMD, interventricular mechanical delay; LVEDD, left ventricular end-diastolic diameter; LVESV, left ventricular end-systolic volume.
aBetween effect of treatment and ischaemia.
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Table 3 Outcome at 18 months’ follow-up
Value Estimate 95% CI P-value P-value for interaction
a
Difference in mean NYHA
Non-IHD 20.53 20.74 to 20.33 ,0.0001 0.30
IHD 20.69 20.69 ,0.0001
End of study status (odds ratio)
Non-IHD 0.52 0.35 to 0.76 0.0009 0.49
IHD 0.42 0.27 to 0.66 0.0001
Difference in mean MR
Non-IHD 4.77 1.12 to 8.42 0.0109 0.83
IHD 4.16 20.44 to 8.75 0.0755
LVEF (%)
Non-IHD 8.50 10.14 to 6.85 ,0.0001 0.003
IHD 4.53 6.24 to 2.82 ,0.0001
LVESV (cm
3)
Non-IHD 258.52 45.56 to 71.49 ,0.0001 0.01
IHD 235.68 20.80 to 50.56 ,0.0001
NT-proBNP
Non-IHD 21231.24 21992.53 to 2469.96 0.0016 0.97
IHD 21137.89 22441.17 to 165.38 0.0866
Difference in mean QRS
Non-IHD 219.8 225.5 to 214.1 ,0.0001 0.03
IHD 29.7 216.4 to 22.9 0.0052
IHD, ischaemic heart disease; MLWHF, Minnesota living with heart failure questionnaire; MR, mitral regurgitation.
aBetween effect of treatment and ischaemia.
IHD aetiology and CRT outcomes 785might have accounted for the observed trends although it is uncer-
tain whether the degree of dyssynchrony predicts the extent of
improvement in LV function or of mitral regurgitation.
12–16
However, in the long-term, as reported elsewhere, LV function
improved to a lesser extent in patients with IHD, presumably
reﬂecting the relative inability of ventricular scar tissue to
remodel favourably.
17 This observation is further corroborated
by echocardiographic ﬁndings in the MIRACLE study.
18 In that
study, although LV volumes were reduced compared with baseline
values after 12 months of CRT, the percentage of patients demon-
strating progressive reduction of LV size decreased from 6 to 12
months. Further, LVEF improved and LV mass regressed. The
changes observed were greater in non-IHD patients.
18 The trend
for a greater effect of CRT in non-IHD might be explained by a
quantitative effect on more viable tissue (cardiomyocytes) in the
non-IHD group and thus a better substrate for response.
19
This suggests that CRT may exert additional effects on prognosis
than merely improving LV function. The combination of IHD and a
low LVEF predisposes to ventricular arrhythmias, and CRT
reduced sudden cardiac death during long-term follow-up,
suggesting a favourable effect on the arrhythmic substrate.
14
Whether or not speciﬁc patterns or extent of ventricular scar can
predict CRT response has been the subject of several small observa-
tional studies that await conﬁrmation.
14 It may be harder to ﬁnd an
effective pacing site in patients with extensive or postero-lateral
scar, and these patients might get less improvement in ventricular
function and possibly symptoms. However, the studies provide no
adequate data on major morbidity or mortality. Without a control
group, it may be difﬁcult to gauge whether the amount of scar really
inﬂuences the beneﬁts of CRT.
12 Maybe, these patients will do badly
with CRT but much worse without. Only randomized controlled
trials can address such issues robustly. No attempt was made to
deﬁne the extent or distribution of scar in the CARE-HF study. It is
possible that the effect of CRT was heterogeneous within the group
ofpatientswithIHD.ItisknownthatpatientswithIHDandextensive
myocardialviabilityaremorelikelytoshowalargeimprovementinLV
functioninresponsetobeta-blockersandtherearesomesimilardata
with CRT.
20 Whether these greater beneﬁts in LV function translate
into greater beneﬁts on morbidity and mortality is not clear and it
would be premature to jump to such a conclusion.
No attempt was made to measure intraventricular dyssynchrony
in CARE-HF, reﬂecting the then existing and now persisting lack of
consensus on how it should be done. The large trials of CRT have
not relied on measures of intraventricular dyssynchrony and yet
shownbeneﬁt. Small observational trials suggest thatsuchmeasures
mightbeusefulinpatientsselectionbutlackcontrolgroupstoprove
their hypothesis. Moreover, there is evidence that dyssynchrony
changes with physiological stress and over time.
12,21 Many more
patients with heart failure experience dyssynchrony than appears
the case in simple cross-sectional studies of patients at rest. The
feasibility of an approach dependent on repeated stress-
dyssynchronystudies, which might be what is required for thorough
assessment, has not been explored. Indeed, dyssynchrony might be
a near-universal phenomenon in patients with severe LV dilatation
and dysfunction.
16 Certainly, no adequately powered randomized
controlled trial has yet identiﬁed a group of patients with heart
failure in whom CRT is not effective in improving ventricular func-
tion, symptoms, morbidity, and mortality. How to measure dyssyn-
chrony and whether it is truly the substrate for CRT are likely to
remain controversial for some time.
12
Figure 1 Hazard ratio and 95% conﬁdence interval for ischaemic and non-ischaemic subgroups, primary outcome, and all-cause mortality.
................................................................................
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Table 4 Primary and secondary outcomes in patients
with and without ischaemic heart disease
a
Value Hazard
ratio
95% CI P-value P-value for
interaction
b
Primary outcome
Non-IHD 0.46 0.35–0.63 ,0.0001 0.06
IHD 0.71 0.54–0.94 0.018
All-cause mortality
Non-IHD 0.56 0.37–0.83 0.004 0.86
IHD 0.54 0.39–0.76 0.0003
IHD, ischaemic heart disease.
aPrimary outcome combined mortality and hospitalization. Secondary outcome,
all-cause mortality.
bBetween effect of treatment and ischaemia.
G. Wikstrom et al. 786It is possible that the reasons why patients with IHD respond to
CRT are different even if the ultimate effect is similar. In a PET study
performed by Linde and co-workers,
22 myocardial perfusion
improved both patientswith and without IHD. Improvement in per-
fusion may be of greater importance to patients with ﬂow-limiting
coronary disease and an extensive collateral circulation than to
patients with unobstructed coronary arteries. Further, the relation
between the degree of dyssynchrony and QRS width is weak and
cannot explain the differences in response to CRT between the
two groups. Mitral valve insufﬁciency may be due to damage to
the papillary apparatus in patients with IHD as well as due to dilata-
tion of the mitral annulus, and this could account for differences in
response.
23 However, as improvement in mitral regurgitation may
be critically dependent on the site and timing of the ventricular
stimuli, the aetiology of heart failure may not be an overriding
factor in clinical practice, as suggested by this study.
24–28
Inevitably, data on mechanistic outcomes used here to attempt
to describe any differences between the ischaemic and non-
ischaemic groups in response to treatment are not available for
all subjects. It was possible to determine ischaemic status in all
but one subject in the trial. Ejection fraction, end-systolic volume
index, and intraventricular mechanical delay were available in
.80% of surviving subjects at 3 months. Ejection fraction and end-
systolic volume index were also available in nearly 70% of subjects
at 18 months. Difﬁculties in measurement led to only 66% of avail-
able subjects providing a mitral regurgitation index score at 3
Figure 2 Kaplan–Meier estimates of the time to the primary endpoint (A) and the secondary endpoint death from any cause (B) according to
aetiology.
IHD aetiology and CRT outcomes 787months, and 52% at 18 months. Left ventricular end-diastolic diam-
eter was subject to considerable missing data (21% of surviving
subjects provided a measure at 3 months). Outcome data were
available on a substantially higher proportion of subjects, with 3
month Minnesota Living with Heart Failure data available on 86%
of subjects, and at 18 months, 94% of subjects provided NYHA
data and 100% provided end of study status. All randomized sub-
jects provided data on mortality and the primary outcome.
In conclusion, despite smaller long-term improvements in LV
function in patients with IHD, the relative beneﬁts of CRT on mor-
bidity and mortality are similar in patients with and without IHD.
However, as patients with IHD generally have a worse prognosis,
the absolute reduction in mortality tends to be greater in this
group. This dissociation between improvement in LV function
and reduction in mortality suggests that CRT may exert effects
beyond LV remodelling, perhaps by reducing the arrhythmic sub-
strate. These data suggest that improvement in LV function may
not be a good surrogate for the effects on mortality unless the
aetiology of LV dysfunction is taken into account.
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